1. Selenium and vitamin B 6 cosupplementation improves dyslipidemia and fatty liver syndrome by SIRT1/SREBP-1c pathway in hyperlipidemic Sprague-Dawley rats induced by high-fat diet.
- Author
-
Zhang Q, Zhou X, Zhang J, Li Q, and Qian Z
- Subjects
- Animals, Apolipoproteins B, Aspartate Aminotransferases metabolism, Cholesterol metabolism, Cholesterol, HDL, Cholesterol, LDL metabolism, Coenzyme A metabolism, Coenzyme A pharmacology, Coenzyme A therapeutic use, Diet, High-Fat adverse effects, Fatty Acids metabolism, Lipase metabolism, Lipase pharmacology, Lipase therapeutic use, Lipid Metabolism, Liver metabolism, Oxidoreductases metabolism, Oxidoreductases pharmacology, Oxidoreductases therapeutic use, PPAR alpha metabolism, RNA, Messenger metabolism, Rats, Rats, Sprague-Dawley, Sirtuin 1 metabolism, Sterol Regulatory Element Binding Protein 1 metabolism, Triglycerides metabolism, Vitamin B 6, Vitamins pharmacology, Fatty Liver metabolism, Hyperlipidemias drug therapy, Selenium pharmacology, Selenium therapeutic use, Trace Elements pharmacology, Trace Elements therapeutic use
- Abstract
Previously, our group found that the dietary trace mineral element selenium and vitamin B
6 (VitB6 ) alone was involved in lipid metabolism. However, the effects of selenium combined with VitB6 on hyperlipidemia and lipid metabolism have not been reported until now. We hypothesized that selenium and VitB6 cosupplementation would alleviate the hyperlipidemic and hepatic dysfunction and with minimum side effects in a Sprague-Dawley rat model of hyperlipidemia induced by a high-fat diet. Our results showed that selenium combined with VitB6 could improve dyslipidemia and displayed better in vivo hypocholesterolemic abilities at early intervention. Moreover, cosupplementation reduced atherogenic indexes (atherogenic index and atherogenic index of plasm) and the ratio of ApoB/ApoA1. The liver function index aspartate aminotransferase in serum was reduced, as was and total cholesterol, triacylglycerol, and low-density lipoprotein cholesterol in liver. The intervention also increased the levels of ApoA1 in serum and high-density lipoprotein cholesterol of liver. In addition, the combination of selenium and VitB6 decreased liver lipid deposition and alleviated steatosis, reduced adipocyte size of white adipose tissue, increased the activities of hepatic lipase and total lipase and the hepatic 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMGR) level, decreased the hepatic mRNA transcription of lipogenic and regulatory genes including Srebf1 and downstream fat synthesis-related enzymes (Acc and Fasn) and cholesterol synthesis speed limiting enzyme Hmgr, increased the mRNA abundance of Lcat and Cyp7a1, increased the protein expression of SIRT1 and PPARα, and up-regulated the protein expression of sterol regulatory element-binding protein 1c in the livers of hyperlipidemia rats. We first demonstrated that oral selenium and VitB6 cosupplementation exerted synergism in lowering blood and liver lipid profiles and antiatherosclerotic effects in hyperlipidemic rats by reducing endogenous cholesterol and lipid synthesis, enhancing the transport of cholesterol to hepatocytes and promoting fatty acid beta oxidation., Competing Interests: Author Declarations The authors declare no conflicts of interest., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF